KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to 0.8.

  • Biomarin Pharmaceutical's Equity Ratio rose 66.33% to 0.8 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.8, marking a year-over-year increase of 66.33%. This contributed to the annual value of 0.81 for FY2024, which is 1185.82% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Equity Ratio of 0.8 as of Q3 2025, which was up 66.33% from 0.81 recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Equity Ratio registered a high of 0.81 during Q1 2025, and its lowest value of 0.71 during Q4 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.73 (2023), whereas its average is 0.75.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Equity Ratio soared by 1779.71% in 2021 and then plummeted by 64.91% in 2023.
  • Biomarin Pharmaceutical's Equity Ratio (Quarter) stood at 0.71 in 2021, then rose by 1.64% to 0.72 in 2022, then increased by 0.23% to 0.72 in 2023, then grew by 11.86% to 0.81 in 2024, then decreased by 1.75% to 0.8 in 2025.
  • Its last three reported values are 0.8 in Q3 2025, 0.81 for Q2 2025, and 0.81 during Q1 2025.